Delayed-type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide-based therapeutic immunization for chronic HIV infection

APMIS

Volumn 120, Issue 3, 2012, Pages 204-209

  Kran, Anne Marte B ^a,b,e   Sommerfelt, Maja A ^c   Baksaas, Ingebjørg ^d   Sørensen, Birger ^c   Kvale, Dag ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Bionor Pharma ASA   (Norway)

^d Mericon AS   (Norway)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Delayed type hypersensitivity reaction; HIV; T cell responses; Therapeutic immunization

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 10; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADJUVANT THERAPY; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IN VITRO STUDY; LOW DRUG DOSE; PRIORITY JOURNAL; SKIN TEST; T LYMPHOCYTE ACTIVATION;

AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FOLLOW-UP STUDIES; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; IMMUNIZATION; INTERFERON-GAMMA; INTERLEUKIN-10; KAPLAN-MEIER ESTIMATE; PROSPECTIVE STUDIES; RNA, VIRAL;

EID: 84857123227     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02843.x     Document Type: Article

References (17)

1. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature 2001;410:980-7.
2. + T-cells. Blood 2006;107:4781-9.
3. Klein MR, Van Baalen CA, Holwerda AM, Kerkhof G Sr, Bende RJ, Keet IP, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365-72.
4. Sáez-Cirión A, Pancino G, Sinet M, Venet A, Lambotte O. ANRS EP36 HIV CONTROLLERS study group. HIV controllers: how do they tame the virus? Trends Immunol 2007;28:532-40.
5. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007;13:46-53.
6. Rolland M, Heckerman D, Deng W, Rousseau CM, Coovadia H, Bishop K, et al. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS ONE 2008;3:e1424.
7. Zuñiga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, Hernandez A, et al. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 2006;80:3122-5.
8. + T cell loss rates in HIV-1 infection. Clin Exp Immunol 2010;161:315-23.
9. Kran AMB, Sorensen B, Nyhus J, Sommerfelt M, Baksaas I, Bruun JN, et al. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS 2004;18:1875-83.
10. Kran AMB, Sommerfelt MA, Sorensen B, Nyhus J, Baksaas I, Bruun JN, et al. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization. Vaccine 2005;23:4011-5.
11. Kran AMB, Sorensen B, Sommerfelt MA, Nyhus J, Baksaas I, Kvale D. Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells. AIDS 2006;20:627-30.
12. Kran AMB, Jonassen TØ, Sommerfelt MA, Løvgården G, Sørensen B, Kvale D. Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides. AIDS 2010;24:2609-18.
13. Asjö B, Stavang H, Sørensen B, Baksaas I, Nyhus J, Langeland N. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy. AIDS Res Hum Retroviruses 2002;18:1357-65.
14. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. International AIDS Society-USA panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-43.
15. Cytokine Detection in Antigen-Activated CD8+ and CD4+ T Cells pdf.
16. Sommerfelt MA, Sørensen B. Prospects for HIV-1 therapeutic immunisation and vaccination: the potential contribution of peptide immunogens. Expert Opin Biol Ther 2008;8:745-57.
17. Kvale D, Kran AMB, Sommerfelt M, Nyhus J, Baksaas I, Bruun JN, et al. Divergent in vitro and in vivo correlates of HIV-specific T cell responses during onset of HIV viremia. AIDS 2005;19:563-7.